Advanced in Cluster Headache

Kirill V. Skorobogatykh

Moscow, MOW, RU 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Cluster Headache
Moscow, MOW, RU 
OverviewLocationsClinical Research

Overview

Kirill Skorobogatykh practices in Moscow, Russian Federation. Mr. Skorobogatykh is rated as an Advanced expert by MediFind in the treatment of Cluster Headache. His top areas of expertise are Headache, Migraine, and Cluster Headache.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Moscow, MOW, Russian Federation

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study
Enrollment Status: Completed
Publish Date: March 28, 2023
Intervention Type: Drug
Study Drug: Galcanezumab
Study Phase: Phase 3
Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
View 2 Less Clinical Trial

10 Total Publications

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
Journal: The journal of headache and pain
Published: May 18, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Skorobogatykh's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile